Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 92, Issue , 2019, Pages 1-7

  Shariq, Aisha S ^a,i   Rosenblat, Joshua D ^a,b   Alageel, Asem ^a,c   Mansur, Rodrigo B ^a,b   Rong, Carola ^a   Ho, Roger C ^d,e   Ragguett, Renee Marie ^a   Pan, Zihang ^a,f   Brietzke, Elisa ^a,g   McIntyre, Roger S ^a,b,f,h  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c AL IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY IMSIU   (Saudi Arabia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY OF TORONTO   (Canada)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^h BRAIN AND COGNITION DISCOVERY FOUNDATION   (Canada)

ⁱ Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Circadian rhythm; Hypocretin; Insomnia; Major depressive disorder; Orexin antagonists; Orexins; Sleep; Suvorexant; Treatment

Indexed keywords

OREXIN; OREXIN RECEPTOR; OREXIN RECEPTOR ANTAGONIST;

CIRCADIAN RHYTHM; HUMAN; INSOMNIA; MAJOR DEPRESSION; NERVE CELL; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN FUNCTION; REVIEW; SLEEP WAKING CYCLE; ANIMAL; DEPRESSION; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SLEEP;

ANIMALS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; HUMANS; OREXIN RECEPTOR ANTAGONISTS; OREXIN RECEPTORS; OREXINS; SLEEP;

EID: 85058974423     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2018.12.008     Document Type: Review

References (53)

1. Adamantidis, A.R., Zhang, F., Aravanis, A.M., Deisseroth, K., de Lecea, L., Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450:7168 (2007), 420–424.
2. Allard, J.S., Tizabi, Y., Shaffery, J.P., Trouth, C.O., Manaye, K., Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides 38:5 (2004), 311–315.
3. Allard, J.S., Tizabi, Y., Shaffery, J.P., Manaye, K., Effects of rapid eye movement sleep deprivation on hypocretin neurons in the hypothalamus of a rat model of depression. Neuropeptides 41:5 (2007), 329–337.
4. Arendt, D.H., Ronan, P.J., Oliver, K.D., Callahan, L.B., Summers, T.R., Summers, C.H., Depressive behavior and activation of the orexin/hypocretin system. Behav Neurosci 127:1 (2013), 86–94.
5. Berridge, C.W., Espana, R.A., Hypocretins: Waking, Arousal, or Action?. Neuron 46:5 (2005), 696–698.
6. Bettica, P., Squassante, L., Groeger, J.A., Gennery, B., Winsky-Sommerer, R., Dijk, D.J., Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37:5 (2012), 1224–1233.
7. Brundin, L., Petersen, A., Bjorkqvist, M., et al. Orexin and psychiatric symptoms in suicide attempters. J Affect Disord. 100:1–3 (2007), 259–263.
8. Brundin, L., Björkqvist, M., Träskman-Bendz, L., Petersén, A., Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J Affect Disord 113:1-2 (2009), 179–182.
9. Bunney, B.G., Bunney, W.E., Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. Biol. Psychiatry 73:12 (2013 Jun 15), 1164–1171.
10. Chung, H.S., Kim, J.G., Kim, J.W., Kim, H.W., Yoon, B.J., Orexin administration to mice that underwent chronic stress produces bimodal effects on emotion-related behaviors. Regul Pept 194–195 (2014), 16–22.
11. Coleman, P.J., Schreier, J.D., Cox, C.D., Breslin, M.J., Whitman, D.B., Bogusky, M.J., GB, McGaughey, Bednar, R.A., Lemaire, W., Doran, S.M., Fox, S.V., Garson, S.L., Gotter, A.L., Harrell, C.M., Reiss, D.R., Cabalu, T.D., Cui, D., Prueksaritanont, T., Stevens, J., Tannenbaum, P.L., Ball, R.G., Stellabott, J., et al. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2- yl)oxy]methyl}-2methylpiperidin-1-yl][5-methyl-2 -(pyrimidin-2-yl) phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 7:3 (2012), 415–424.
12. Cox, C.D., Breslin, M.J., Whitman, D.B., Schreier, J.D., McGaughey, G.B., Bogusky, M.J., Roecker, A.J., Mercer, S.P., Bednar, R.A., Lemaire, W., Bruno, J.G., Reiss, D.R., Harrell, C.M., Murphy, K.L., Garson, S.L., Doran, S.M., Prueksaritanont, T., Anderson, W.B., Tang, C., Roller, S., Cabalu, T.D., Cui, D., et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-Yl)-7-methyl-1,4-diazepan-1-Yl][5-methyl-2-(2H -1,2,3-triazol-2-Yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 53:14 (2010), 5320–5332.
13. Deats, S.P., Adidharma, W., Lonstein, J.S., Yan, L., Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency. Neuroscience 272 (2014), 252–260.
14. Di Fabio, R., Pellacani, A., Faedo, S., Roth, A., Piccoli, L., Gerrard, P., Porter, R.A., Johnson, C.N., Thewlis, K., Donati, D., Stasi, L., Spada, S., Stemp, G., Nash, D., Branch, C., Kindon, L., Massagrande, M., Poffe, A., Braggio, S., Chiarparin, E., Marchioro, C., Ratti, E., et al. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg Med Chem Lett 21:18 (2011), 5562–5567.
15. Eban-Rothschild, A., Giardino, W., de Lecea, L., To sleep or not to sleep: neuronal and ecological insights. Curr Opin Neurobiol. 44 (2017), 132–138.
16. Feng, P., Hu, Y., Vurbic, D., Akladious, A., Strohl, K.P., Chromosome 1 replacement increases brain orexins and antidepressive measures without increasing locomotor activity. J Psychiatr Res 59 (2014), 140–147.
17. Franzen, P.L., Buysse, D.J., Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci 10:4 (2008), 473–481.
18. Giardino, W.J., de Lecea, L., Hypocretin (orexin) neuromodulation of stress and reward pathways. Curr. Opin. Neurobiol., 2014, 103–108.
19. Gotter, A.L., Forman, M.S., Harrell, C.M., Stevens, J., Svetnik, V., Yee, K.L., Li, X., Roecker, A.J., Fox, S.V., Tannenbaum, P.L., Garson, S.L., Lepeleire, I.D., Calder, N., Rosen, L., Struyk, A., Coleman, P.J., Herring, W.J., Renger, J.J., Winrow, C.J., Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man. Sci Rep, 6, 2016, 27147.
20. Harris, G.C., Aston-Jones, G., Arousal and reward: A dichotomy in orexin function. Trends Neurosci 29:10 (2006), 571–577.
21. Herring, W.J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., Lines, C., Roth, T., Michelson, D., Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant. Neurology 79:23 (2012), 2265–2274, 10.1212/WNL.
22. Hoever, P., de Haas, S.L., Dorffner, G., Chiossi, E., van Gerven, J.M., Dingemanse, J., Orexin receptor antagonism: An ascending multiple-dose study with almorexant. J Psychopharmacol 26:8 (2012), 1071–1080, 10.1177/0269881112448946.
23. Jalewa, J., Wong-Lin, K., McGinnity, T.M., Prasad, G., Hölscher, C., Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression. Behav Brain Res 272 (2014), 196–204, 10.1016/j.bbr.2014.05.030.
24. Kim, T.K., Kim, J.E., Park, J.Y., Lee, J.E., Choi, J., Kim, H., Lee, E.H., Kim, S.W., Lee, J.K., Kang, H.S., Han, P.L., Antidepressant effects of exercise are produced via suppression of hypocretin/orexin and melanin-concentrating hormone in the basolateral amygdala. Neurobiol Dis 79 (2015), 59–69, 10.1016/j.nbd.2015.04.004.
25. Kuriyama, A., Tabata, H., Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med Rev 35 (2017), 1–7.
26. Ling, A., Lim, M.L., Gwee, X., Ho, R.C., Collinson, S.L., Ng, T., Insomnia and daytime neuropsychological test performance in older adults. Sleep Med 17 (2016), 7–12.
27. Lutter, M., Krishnan, V., Russo, S.J., Jung, S., McClung, C.A., Nestler, E.J., Orexin signaling mediates the antidepressant-like effect of calorie restriction. J Neurosci 28:12 (2008), 3071–3075.
28. Michelson, D., Snyder, E., Paradis, E., Chengan-Liu, M., Snavely, D.B., Hutzelmann, J., Walsh, J.K., Krystal, A.D., Benca, R.M., Cohn, M., Lines, C., Roth, T., Herring, W.J., Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:5 (2014), 461–471, 10.1016/S1474-4422(14)70053-5.
29. Mikrouli, E., Wörtwein, G., Soylu, R., Mathé, A.A., Petersén, Å., Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides 45:6 (2011), 401–406.
30. Murphy, P., Moline, M., Mayleben, D., Rosenberg, R., Zammit, G., Pinner, K., Dhadda, S., Hong, Q., Giorgi, L., Satlin, A., A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results from a Bayesian, Adaptive, Randomized, Double-blind, Placebo-Controlled Study. J Clin Sleep Med 13:11 (2017), 1289–1299.
31. Nakamura, M., Nagamine, T., Neuroendocrine, autonomic, and metabolic responses to an Orexin Antagonist, Suvorexant, in Psychiatric patients with Insomnia. Innov Clin Neurosci 14:3-4 (2017), 30–37.
32. Nierenberg, A.A., Husain, M.M., Trivedi, M.H., Fava, M., Warden, D., Wisniewski, S.R., Miyahara, S., Rush, A.J., Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol. Med. 40:1 (2010 Jan), 41–50.
33. Nollet, M., Leman, S., Role of orexin in the pathophysiology of depression: Potential for pharmacological intervention. CNS Drugs 27:6 (2013), 411–422, 10.1007/s40263-013-0064-z.
34. Nollet, M., Gaillard, P., Tanti, A., Girault, V., Belzung, C., Leman, S., Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 37:10 (2012), 2210–2221.
35. Palagini, L., Baglioni, C., Ciapparelli, A., Gemignani, A., Riemann, D., REM sleep dysregulation in depression: State of the art. Sleep Med Rev 17:5 (2013), 377–390, 10.1016/j.smrv.2012.11.001.
36. Pałasz, A., Lapray, D., Peyron, C., Rojczyk-Gołębiewska, E., Skowronek, R., Markowski, G., Czajkowska, B., Krzystanek, M., Wiaderkiewicz, R., Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders. Int J Neuropsychopharmacol. 17:1 (2014), 157–168.
37. Pålhagen, S., Qi, H., Mårtensson, B., Wålinder, J., Granérus, A.K., Svenningsson, P., Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol 257:4 (2010), 524–532.
38. Peyron, C., Tighe, D.K., van den Pol, A.N., de Lecea, L., Heller, H.C., Sutcliffe, J.G., Kilduff, T.S., Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:23 (1998), 9996–10015.
39. Piccoli, L., Micioni Di Bonaventura, M.V., Cifani, C., Costantini, V.J., Massagrande, M., Montanari, D., Martinelli, P., Antolini, M., Ciccocioppo, R., Massi, M., Merlo-Pich, E., Di Fabio, R., Corsi, M., Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology 37:9 (2012), 1999–2011.
40. Puri, B., Hall, A., Ho, R.C., (eds.) Revision Notes in Psychiatry, 3rd edn, 2014, New York, CRC Press.
41. Ragguett, R.M., Cha, D.S., Kakar, R., Rosenblat, J.D., Lee, Y., Assessing and measuring cognitive function in major depressive disorder. Evid Based Ment Health 19:4 (2016), 106–109.
42. Rainero, I., Ostacoli, L., Rubino, E., Gallone, S., Picci, L.R., Fenoglio, P., Negro, E., Rosso, C., De Martino, P., De Marchi, M., Furlan, P.M., Pinessi, L., Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord 130:3 (2011), 487–491.
43. Rosenberg, R.P., Sleep maintenance insomnia: Strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 18:1 (2006), 49–56.
44. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, S.C., Richardson, J.A., Kozlowski, G.P., Wilson, S., Arch, J.R., Buckingham, R.E., Haynes, A.C., Carr, S.A., Annan, R.S., McNulty, D.E., Liu, W.S., Terrett, J.A., Elshourbagy, N.A., Bergsma, D.J., Yanagisawa, M., Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:4 (1998), 573–585.
45. Salomon, R.M., Ripley, B., Kennedy, J.S., Johnson, B., Schmidt, D., Zeitzer, J.M., Nishino, S., Mignot, E., Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 54:2 (2003), 96–104.
46. Scammell, T.E., Winrow, C.J., Annual review of pharmacology and toxicology. Orexin Receptors 51 (2011), 243–266.
47. Schmidt, F.M., Brügel, M., Kratzsch, J., Strauss, M., Sander, C., Baum, P., Thiery, J., Hegerl, U., Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neurosci Lett 483:1 (2010), 20–22.
48. Schmidt, F.M., Arendt, E., Steinmetzer, A., Bruegel, M., Kratzsch, J., Strauss, M., Baum, P., Hegerl, U., Schönknecht, P., CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res 190:2–3 (2011), 240–243.
49. Smeraldi, E., Delmonte, D., Agomelatine in depression. Expert Opin Drug Saf 12:6 (2013), 873–880.
50. Takenoshita, S., Sakai, N., Chiba, Y., Matsumura, M., Yamaguchi, M., Nishino, S., An overview of hypocretin based therapy in narcolepsy. Expert Opin Investig Drugs. 27:4 (2018), 389–406.
51. Winrow, C.J., Gotter, A.L., Cox, C.D., Doran, S.M., Tannenbaum, P.L., Breslin, M.J., Garson, S.L., Fox, S.V., Harrell, C.M., Stevens, J., Reiss, D.R., Cui, D., Coleman, P.J., Renger, J.J., Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet. 25:1-2 (2011), 52–61.
52. Winrow, C.J., Gotter, A.L., Cox, C.D., Tannenbaum, P.L., Garson, S.L., Doran, S.M., Breslin, M.J., Schreier, J.D., Fox, S.V., Harrell, C.M., Stevens, J., Reiss, D.R., Cui, D., Coleman, P.J., Renger, J.J., Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology 62:2 (2012), 978–987.
53. Zisapel, Drugs for insomnia. Expert Opin Emerg Drugs 17:3 (2012), 299–317.